Luisa Quinti
Overview
Explore the profile of Luisa Quinti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
787
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yeganeh P, Kwak S, Jorfi M, Koler K, Kalatturu T, von Maydell D, et al.
Neuron
. 2024 Nov;
113(2):205-224.e8.
PMID: 39610246
Alzheimer's disease (AD) presents a complex pathological landscape, posing challenges to current therapeutic strategies that primarily target amyloid-β (Aβ). Using a novel integrative pathway activity analysis (IPAA), we identified 83...
2.
Kim E, Kim H, Jedrychowski M, Bakiasi G, Park J, Kruskop J, et al.
Neuron
. 2023 Sep;
111(22):3619-3633.e8.
PMID: 37689059
A pathological hallmark of Alzheimer's disease (AD) is the deposition of amyloid-β (Aβ) protein in the brain. Physical exercise has been shown to reduce Aβ burden in various AD mouse...
3.
Boyarko B, Podvin S, Greenberg B, Momper J, Huang Y, Gerwick W, et al.
Front Pharmacol
. 2023 Aug;
14:1190402.
PMID: 37601062
Therapeutics discovery and development for Alzheimer's disease (AD) has been an area of intense research to alleviate memory loss and the underlying pathogenic processes. Recent drug discovery approaches have utilized...
4.
Liang Y, Lee D, Zhen S, Sun H, Zhu B, Liu J, et al.
Phytomedicine
. 2022 Jun;
104:154158.
PMID: 35728383
Background: Based on the complex pathology of AD, a single chemical approach may not be sufficient to deal simultaneously with multiple pathways of amyloid-tau neuroinflammation. A polydrug approach which contains...
5.
Shoup T, Griciuc A, Normandin M, Quinti L, Walsh L, Dhaynaut M, et al.
J Alzheimers Dis
. 2021 Feb;
80(2):775-786.
PMID: 33579853
Background: Cromolyn is an anti-neuroinflammatory modulator with a multifactorial mechanism of action that has been shown to inhibit amyloid-β (Aβ) aggregation and enhance microglial uptake and clearance of Aβ. Objective:...
6.
Zhang C, Griciuc A, Hudry E, Wan Y, Quinti L, Ward J, et al.
Sci Rep
. 2018 Jan;
8(1):1144.
PMID: 29348604
Amyloid-beta protein (Aβ) deposition is a pathological hallmark of Alzheimer's disease (AD). Aβ deposition triggers both pro-neuroinflammatory microglial activation and neurofibrillary tangle formation. Cromolyn sodium is an asthma therapeutic agent...
7.
Quinti L, Naidu S, Trager U, Chen X, Kegel-Gleason K, Lleres D, et al.
Proc Natl Acad Sci U S A
. 2017 May;
114(23):E4676-E4685.
PMID: 28533375
The activity of the transcription factor nuclear factor-erythroid 2 p45-derived factor 2 (NRF2) is orchestrated and amplified through enhanced transcription of antioxidant and antiinflammatory target genes. The present study has...
8.
Wagner S, Rynearson K, Duddy S, Zhang C, Nguyen P, Becker A, et al.
J Pharmacol Exp Ther
. 2017 Apr;
362(1):31-44.
PMID: 28416568
Alzheimer's disease (AD) is characterized neuropathologically by an abundance of 1) neuritic plaques, which are primarily composed of a fibrillar 42-amino-acid amyloid- peptide (A), as well as 2) neurofibrillary tangles...
9.
Chopra V, Quinti L, Khanna P, Paganetti P, Kuhn R, Young A, et al.
J Huntingtons Dis
. 2016 Dec;
5(4):347-355.
PMID: 27983565
Background: Modulation of gene transcription by HDAC inhibitors has been shown repeatedly to be neuroprotective in cellular, invertebrate, and rodent models of Huntington's disease (HD). It has been difficult to...
10.
Choi S, Kim Y, Quinti L, Tanzi R, Kim D
Mol Neurodegener
. 2016 Dec;
11(1):75.
PMID: 27938410
Alzheimer's disease (AD) transgenic mice have been used as a standard AD model for basic mechanistic studies and drug discovery. These mouse models showed symbolic AD pathologies including β-amyloid (Aβ)...